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Abstract
Background: Rotational thromboelastography (ROTEG) has been proposed as a monitoring tool
that can be used to monitor treatment of hemophilia with recombinant factor VIIa (rFVIIa). In these
studies special non-standard reagents were used as activators of the coagulation. The aim of this
study was to evaluate if standard ROTEG analysis could be used for monitoring of effects of
recombinant factor VIIa (rFVIIa) on Hydroxy Ethyl Starch-induced dilutional coagulopathy.
Methods: The study was performed in vitro on healthy volunteers. Prothrombin time (PT) and
ROTEG analysis were performed after dilution with 33% hydroxy ethyl starch and also after
addition of rFVIIa to the diluted blood.
Results: PT was impaired with INR changing from 0.9 before dilution to 1.2 after dilution while
addition of rFVIIa to diluted blood lead to an overcorrection of the PT to an International
Normalized Ratio (INR) value of 0.6 (p = 0.01). ROTEG activated with the contact activator ellagic
acid was impaired by hemodilution (p = 0.01) while addition of rFVIIa had no further effects.
ROTEG activated with tissue factor (TF) was also impaired by hemodilution (p = 0.01) while
addition of rFVIIa lead to further impairment of the coagulation (p = 0.01).
Conclusions: The parameters affected in the ROTEG analysis were Clot Formation Time and
Amplitude after 15 minutes while the Clotting Time was unaffected. We believe these effects to be
due to methodological problems when using standard activators of the coagulation in the ROTEG
analysis in combination with rFVIIa.
Background
Patients undergoing massive hemorrhage experience dilu-
tional coagulopathy with crystalloid and/or colloid resus-
citation. If hemorrhage progresses, packed red cells (RBC)
are transfused together with crystalloids and/or colloids.
Regarding the coagulation this is not optimal, and the
patients often develop a dilutional coagulopathy, some-
times worsened by hypothermia. In addition a coagulop-
athy caused by the administration of dextrane or hydroxy
ethyl starch (HES) may be induced. The common
approach to this is transfusion of fresh frozen plasma
(FFP) and platelets, but bleeding might continue, with
often fatal outcome. Prophylactic use of fresh frozen
plasma (FFP) or platelet transfusion is not proven
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beneficial to prevent hemorrhage in massively transfused
patients[1]. Hemorrhage, complicated by the develop-
ment of coagulopathy, is therefore still the major cause of
death in trauma patients arriving alive in the
hospital.[2,3].
A novel approach to treat these patients is the use of
recombinant factor VIIa (rFVIIa) to improve the coagula-
tion.[4]. Recently there have been several case publica-
tions of successful treatment of coagulopathic trauma
patients and surgical patients. [5-7].
Dilutional coagulopathy can be detected by the use of
thromboelastographic measurements [8-11]. Rotational
thromboelastography (ROTEG) is a recent development
of thromboelastography. ROTEG gives a viscoelastic
measurement of clot strength in whole blood. It is pre-
sented as a graph representing clot strength during the
build-up of a clot (figures 1 and 2). From the graph several
variables describing different parts of the coagulation
process are derived and measured numerically. It thus
gives a more comprehensive picture of the coagulation
than standard tests, but is on the other hand less validated
and standardised than the more common coagulation
tests. An advantage of the method is that it can be used as
a point-of-care analysis. One condition to be fulfilled if it
should be used as a point-of-care method is that the com-
mercially available kits can be used for analysis and that
special preparations and/or dilutions should not be nec-
essary, as that would require the skills and competencies
of a full laboratory.
Previous studies have shown that hemodilution with HES
impairs the coagulation already at a dilution of 33% while
crystalloid hemodilution does not appear to give a readily
detectable impairment of the coagulation until the level
of hemodilution reaches 50% [10,12]. In this study we
have investigated if ROTEG can be used with the commer-
cially available kits to monitor effects of rFVIIa and if
rFVIIa is able to improve the coagulopathy caused by
hemodilution with HES.
Methods
The local ethics committee of the University of Lund
approved this study on healthy volunteers. Volunteers
were not allowed to take any medication 14 days prior to
the study. Informed consent was obtained from the partic-
ipants and a total of eight were recruited. All participants
had an indwelling intravenous catheter placed into the
brachiocephalic vein, from which the blood samples were
drawn with sterile disposable 5-ml syringes (Luer; Codan
Medical Aps, Rödby, Denmark). A first 5-ml blood sample
was discarded before every blood sample for the experi-
ment described below. No tourniquet was used on the
arm when samples were drawn.
The figure shows the 3 representative tracings of the EXTEG  analysis from one of the participants in the study Figure 1
The figure shows the 3 representative tracings of the EXTEG 
analysis from one of the participants in the study. Above the 
normal tracing with a short CT and CFT is shown. It can be 
seen that the clot strength is rapidly increasing after initiation 
of the clotting. In the middle the tracing after hemodilution 
with HES is found. It can be seen that the CFT is prolonged 
and that the strength of the clot is increasing slower. Below 
the tracing after hemodilution and addition of rFVIIa is found. 
The clotting is then severely impaired, the clot strength is 
increasing slower and the maximum strength is also severely 
impaired.BMC Blood Disorders 2005, 5:3 http://www.biomedcentral.com/1471-2326/5/3
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Dilution of the blood samples was performed with HES
130/0.4 (Voluven®, Fresenius Co., Bad Homburg, Ger-
many), the HES preparation found to cause the least pro-
nounced coagulopathy after hemodilution [12]. Three
different preparations of blood were examined. The first
preparation contained 5 ml of undiluted blood (normal).
The second preparation contained 3.3 ml of blood and
1.7 ml of HES thereby achieving a 33% dilution (dilu-
tion). The third preparation contained 3.3 ml of blood,
1.7 ml of HES and 50µl of rFVIIa at the concentration 0.12
µg/µl (dilution + rFVIIa). The latter concentration of
rFVIIa was equivalent to the concentration achieved when
the dose 90 µg/kg body weight is administered in vivo. 90
µg/kg is the recommended dose in hemophilia and well
within the range suggested for treatment of acute hemor-
rhage in non hemophilia patients.[7,13]. The reason for
the chosen dilution (33%) was that it is a clinically rele-
vant dilution that is readily achieved during resuscitation
of a patient. Before initiating this study we have also tested
50% dilution in a single person and the results were sim-
ilar to the results with 33% dilution, but more pro-
nounced. We then decided to study the 33% dilution
systematically. Further on, this dilution did not induce
unphysiologic changes in Ca or pH as tested in a pilot vol-
unteer. The dilution was performed in a polypropylene
test tube and the tube was gently turned to mix the blood
with the added HES and rFVIIa. The HES was warmed in
a heating block (Grant Instrumentation Ltd, Cambridge,
UK) to 37°C prior to hemodilution in order to avoid
hypothermia as a confounding factor after dilution.
The tests performed on the different preparations were
hemoglobin concentration (Hb), Prothrombin time (PT)
and ROTEG analysis. All tests were performed at normal
body temperature (37°C). For the Hb measurements a
Hemocue (HemoCue Co., Ängelholm, Sweden) was used.
PT measurements were performed with a Rapidpoint
Coag Analyzer (Bayer AB Diagnostics, Gothenburg, Swe-
den) with PT-ONE test cards. The ROTEG analyses were
performed on a Rotational Thromboelastograph (ROTEG,
Pentapharm, Munich, Germany) and the samples were
analysed 120 seconds after the blood was drawn from the
intravenous catheter. Both INTEG and EXTEG analyses
were performed according to standard procedure recom-
mended by the manufacturer. In INTEG analysis the coag-
ulation is initiated with the addition of 20 µl of the
contact activator ellagic acid (Pentapharm, Munich, Ger-
many) to 320 µl of blood pipetted from the test tube to a
reaction cup used in the ROTEG. In EXTEG analysis the
coagulation is activated by the addition of 20 µl of a prep-
aration containing tissue factor (TF) (Pentapharm,
Munich, Germany) to 320 µl of blood pipetted from the
test tube to the reaction cup. TF activates the coagulation
through binding to Factor VIIa and this is believed to be
the important interaction when in vivo coagulation
occurs. The parameters obtained from the ROTEG analysis
were Clotting Time (CT) reflecting the initiation of the
coagulation, Clot Formation Time (CFT) reflecting the
rate of clot formation once the formation is initiated and
A15 describing the strength of the clot 15 minutes after
initiation of the coagulation (figure 2).
Statistical analysis was performed with initial Kruskal-
Wallis test and Wilcoxon's paired test was used when the
Kruskal-Wallis test indicated a significant difference. All
values are given as median (range). A p value of < 0.05 was
considered statistically significant.
Results
The insertion of venous catheters and the blood sampling
were performed uneventfully. The Hb values decreased as
an expected sign of dilution (table 1). PT values increased
in the dilution group compared to normal and decreased
to below normal in the dilution + rFVIIa group (table 1).
In neither INTEG nor EXTEG analysis we found any
change in the CT between normal and dilution groups,
while CFT and A15 were impaired in the dilution group
(tables 2 and 3). There were no differences between the
The figure shows the result of a ROTEG analysis Figure 2
The figure shows the result of a ROTEG analysis. Time is 
represented on the X axis and clot strength on the Y axis. 
The clot strength is arbitrarily measured in mm where maxi-
mum clot strength is 100 mm. The Clotting Time (CT) is the 
time from initiation of the analysis until the clot strength is 2 
mm. The Clot Formation Time (CFT) is the time from clot 
strength 2 mm until clot strength 20 mm. A15 is the clot 
strength at 15 minutes.
ROTEG registration
CT (s) CFT (s)
A15 (mm)
10 min
20 mmBMC Blood Disorders 2005, 5:3 http://www.biomedcentral.com/1471-2326/5/3
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dilution and the dilution + rFVIIa groups when analysed
with the INTEG analysis (table 2). However, when rFVIIa
was added to the dilution a prolongation of the CFT with
> 200% and an impairment of the A15 with 40% were
found (table 3 and figure 1).
Discussion
Treatment of dilutional coagulopathy is challenging and
the primary monitoring tools are measurement of PT, acti-
vated partial thromboplastin time (APTT), platelet count
and fibrinogen [14-16]. These tests provide us with infor-
mation regarding the activation of the coagulation process
and about the absolute number of platelets. However,
they do not give us information regarding the dynamic
properties of blood clotting and the rate at which the clot
is formed once the clotting is initiated. New monitoring
methods are needed and ROTEG is a monitoring tool that
could potentially be of value in these situations. To this
end, it has been suggested that treatment of haemophilia
patients and liver transplant patients with rFVIIa can be
monitored with ROTEG where a shortening of the CT and
CFT has been found in case series. [17-19].
In our study we found that hemodilution in vitro with
HES lead to augmentation of the PT and the addition of
rFVIIa results in a prompt decrease of the PT. This is in line
with previous studies, which have shown that dilution
with HES lead to readily detectable changes in the coagu-
lation system[9,12,20]. Former studies have also shown a
decrease or a normalisation of the PT after administration
of rFVIIa[21,22]. In this study we found an overcorrection
of the PT to values below normal range.
When analysing the ROTEG parameters we found that the
33% dilution with HES resulted in a prolongation of CFT
values and impairment in A15 values in accordance with
previous studies[9,11,12,20]. The CT was not significantly
prolonged even though there was a trend towards a
Table 1: Effects of dilution and addition of rFVIIa on Hb and PT values. A lowering of Hb and an increase in the PT were seen as signs 
of dilution while the addition of rFVIIa lead to a decrease of the PT (n = 8).
Normal Dilution Dilution + rFVIIa
Hb (g/l) 136 (127–147) 88 (81–99)* 88 (81–99)*
PT (INR) 0.9 (0.7–1.2) 1.2 (0.9–1.3)§ 0.6 (0.5–0.7)*¶
* p = 0.01 compared to normal. ¶p = 0.01 compared to dilution. §p = 0.02 compared to normal.
Table 2: Coagulation variables as assessed by INTEG. Obvious signs of dilution are found in the CFT and the A15, while the addition of 
rFVIIa to the diluted blood does not affect the coagulation parameters (n = 8).
Normal Dilution Dilution + rFVIIa
CT (s) 93.5 (82–104) 108.5 (87–136) 97.5 (68–118)
CFT (s) 85.5 (59–111) 216 (158–310)* 190.5 (167–368)*
A15 (mm) 56 (52–61) 43 (36–47)* 43.5 (33–50)*
* p = 0.01 compared to normal.
Table 3: Coagulation variables as assessed by EXTEG. Obvious signs of dilution are found in the CFT and the A15. The addition of 
rFVIIa to the diluted blood leads to a prolongation of the CFT and the A15 (n = 8).
Normal Dilution Dilution + rFVIIa
CT (s) 51.5 (30–69) 63 (41–81) 58.5 (37–99)
CFT (s) 91 (67–105) 227 (171–332)* 558.5 (308–998)*¶
A15 (mm) 57 (53–63) 42 (33–49)* 25.5 (19–37)*¶
* p = 0.01 compared to normal. ¶p = 0.01 compared to dilution.BMC Blood Disorders 2005, 5:3 http://www.biomedcentral.com/1471-2326/5/3
Page 5 of 6
(page number not for citation purposes)
prolongation of the CT in both INTEG and EXTEG. After
rFVIIa had been added to the diluted blood, coagulation
variables remained unchanged when assessed with
INTEG, but were markedly affected when assessed with
EXTEG. CFT and A15 reflect the dynamic interplay
between platelets and fibrin polymerisation, both being
disturbed by HES hemodilution as can be seen in table 2
and 3. Addition of rFVIIa in vitro, worsening both these
parameters according to EXTEG analysis, suggested that
platelets or fibrinogen became dysfunctional in contrast
to the clinical effect of administration of rFVIIa, where
rFVIIa has been found successful in case stories of bleed-
ing patients [4,7,13,23], even though these cases may not
have been bleeding due to a HES induced coagulopathy.
The lack of effect in the INTEG analysis when adding
rFVIIa to the diluted blood is most likely due to the fact
that a contact activator is used to activate the coagulation
in the INTEG and therefore insensitive to rFVIIa as rFVIIa
initiates coagulation through interaction with TF.
The impairment of CFT and A15 in the EXTEG analysis
after addition of rFVIIa to the diluted blood is harder to
explain. We expected addition of rFVIIa to the diluted
blood to result in an improvement of the TEG parameters
measured in the EXTEG analysis. This was expected partly
because TF is used as an activator of the coagulation in the
EXTEG analysis and the first step in the initiation of the
coagulation system is the interaction between TF and
FVIIa. [17,18,24]. In our study it is likely that the coagu-
lopathy induced was at least to some extent caused by a
platelet dysfunction caused by the colloid hemodilution.
As bleeding caused by Glanzmann's thrombastenia and
other thrombocytopathias is frequently and successfully
treated with rFVIIa, is a reason why rFVIIa potentially
could be effective in the treatment of this HES-induced
coagulopathy[25-28].
The previously reported improvements of coagulation in
hemophilia and liver transplant patients as evaluated with
ROTEG after administration of rFVIIa also lead us to
believe that ROTEG parameters would be improved after
addition of rFVIIa to the diluted blood[17,18,24]. It is
however important that these studies were performed on
hemophilia patients suffering from a severe deficiency of
factor VIII or IX and on liver transplant patients suffering
from a very complex coagulopathy. It also seems impor-
tant to dilute TF extensively to detect the effects of rFVIIa
on ROTEG. Dilutions of TF up to 1:17000 have been per-
formed by the Ingerslev group in Denmark [18,24]. These
dilutions are, however, not made with commercially
available reagents that are ready to use immediately and
therefore not suitable for use outside research
laboratories.
Conclusion
In conclusion we found that 33% dilution of blood with
HES 130/0.4 lead to impairment of the coagulation when
evaluated with ROTEG or PT. Addition of rFVIIa lead to
overcorrection of the prolonged PT. ROTEG analysis
revealed that INTEG analysis was insensitive to effects of
addition of rFVIIa and that EXTEG analysis was dramati-
cally impaired by the addition of rFVIIa. It may well be
that rFVIIa is not effective in improving the coagulopathy
induced by HES hemodilution, but the further impair-
ment of the coagulation seen in the EXTEG analysis is
likely due to methodological problems. These problems
make the commercially available EXTEG analyses inap-
propriate for monitoring of rFVIIa effects under circum-
stances of HES dilution.
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